Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …

Simple Summary Immune checkpoint inhibitors (ICIs) are now a cornerstone of systemic
treatment for hepatocellular carcinoma (HCC). However, their efficacy is blunted by …

The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related
deaths in the world. More than half of patients with HCC present with advanced stage, and …

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …

Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …

Drug development in hepatocellular carcinoma (HCC) has been characterised by many
failures in the past. Despite good rationales and promising phase II data, many phase III …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world
and its incidence is increasing in many countries. In recent years, with the deepening …

In advanced-stage hepatocellular carcinoma (HCC), systemic treatment represents the
standard therapy. Target therapy has marked a new era based on a greater knowledge of …